Recordati SpAMIL:REC +0.88%96 PB Ratio is 5.09 as of Jun. 25, 2026, which is 19% below its 10-year median of 6.26. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Recordati SpA ranks worse than 83.19% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Recordati SpA's share price is €51.55. Recordati SpA's Book Value per Share for the quarter that ended in Mar. 2026 was €10.13. Hence, Recordati SpA's PB Ratio of today is 5.09.
Good Sign:
Recordati SpA stock PB Ratio (=5.02) is close to 3-year low of 4.76.
The historical rank and industry rank for Recordati SpA's PB Ratio or its related term are showing as below:
MIL:REC'
s PB Ratio Range Over the Past 10 Years
Min: 4.5 Med: 6.26 Max: 8.93
Current: 5.06
During the past 13 years, Recordati SpA's highest PB Ratio was 8.93. The lowest was 4.50. And the median was 6.26.
MIL:REC's PB Ratio is ranked worse than 83.19% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs MIL:REC: 5.06
During the past 12 months, Recordati SpA's average Book Value Per Share Growth Rate was 5.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Recordati SpA was 14.20% per year. The lowest was 3.70% per year. And the median was 9.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Recordati SpA PB Ratio Related Terms
Recordati SpA PB Ratio Historical Data
* Premium members only.
The historical data trend for Recordati SpA's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Recordati SpA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's PB Ratio distribution charts can be found below:
* The bar in red indicates where Recordati SpA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Recordati SpA's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Recordati SpA (MIL:REC) has a PB Ratio of 5.09 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Recordati SpA and its competitors. This is 19% below median its historical median of 6.26. Over the past decade, Recordati SpA's PB Ratio has ranged from 4.50 to 8.93. According to the industry distribution chart, Recordati SpA ranks #767 out of 922 companies in the Drug Manufacturers industry, placing it in the top 83.2%.
Is Recordati SpA's PB Ratio too high?
Recordati SpA's current PB Ratio of 5.09 is 19% below median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 4.50 to a high of 8.93. The Drug Manufacturers industry median PB Ratio is 1.88. Recordati SpA's value of 5.09 is 170.7% above this industry median. Based on the distribution chart, Recordati SpA ranks #767 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #767 out of 922 companies for PB Ratio. This places Recordati SpA in the lower half of its industry. The industry median PB Ratio is 1.88. Recordati SpA's value of 5.09 is 170.7% above this benchmark. Historically, Recordati SpA's own PB Ratio has ranged from 4.50 to 8.93 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 1.88, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current PB Ratio of 5.09 is 170.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current PB Ratio is 5.09, which is 19% below median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.64, compared to a current price of €51.55 — trading 15% below its estimated fair value. The current PB Ratio is 5.09, which is 19% below median its 10-year median of 6.26 and 170.7% above the Drug Manufacturers industry median of 1.88. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current PB Ratio is 5.09 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.55 is trading 15% below its estimated GF Value™ of €60.64.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
PB Ratio: 5.09 (19% below median its 10-year median of 6.26)
GF Value™: €60.64 vs. price of €51.55 (15% below fair value)
Industry Position: 170.7% above the Drug Manufacturers median (#767 of 922)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
